EVALUATION OF SOME SALICYALDEHYDE-DERIVED BAYLIS- HILLMAN ADDUCTS AND

Slides:



Advertisements
Similar presentations
A Case of Anaemia Lent term year 1. The case 21 year old Afro-Caribbean man Admitted with abdominal pain and priapism.
Advertisements

Practical Clinical Hematology
Hemoglobin (Hb) Hb is found in RBCs its main function is to transport O2 to tissues. Structure: 2 parts : heme + globin Globin: four globin chains (2 α.
Structural Genomics and Human Health
Prepared by: Ibtisam H. Al Aswad Reham S. Hammad
Hemoglobin (Hb) Hb is found in RBCs its main function is to transport O2 to tissues. Structure: 2 parts : heme + globin Globin: four chains. Heme: porphyrin.
Sickle Cell Mohammed laqqan.
Anemia Dr Gihan Gawish.
Characterization of a potential new drug in cancer therapy Lab 2 Salah Farag.
SICKLE CELL ANEMIA Nada Mohamed Ahmed , MD, MT (ASCP)i.
A Genetic Mutation. – Kavya Ravela
3.1 Genes Understanding: -A gene is a heritable factor that consists of a length of DNA and influences a specific characteristic -A gene occupies a specific.
Practical Clinical Hematology. What is Sickle cell: Sickle cell anemia is an inherited disorder that leads to the production of an abnormal hemoglobin.
Practical Hematology Lab
AROMATIC THIOSEMICARBAZONES ARE INHIBITORS OF TRYPTOPHAN 2,3-DIOXYGENASE (TDO), AN EMERGING TARGET FOR CANCER TREATMENT Introduction and aim of the work.
PRESENTED BY ZOE DANIELS
The Medical Mystery of Sasha Fierce By: Doctors Vanessa L’Abbate, Sarah Danzinger and Lydia Torres.
Haemoglobinopathies.
Anti-angiogenic thalidomide analogs: A determination of their teratogenic potential using a chicken egg embryo model Michelle Abramowski York College of.
Cassie, Abbie, Marie. $1,000  A medical career that is involved with SCD would be: A. Cardiologist B. Blood Spatter Analyst C. Hematologist D. DNA Analyst.
Practical Clinical Hematology
SICKLE CELL DISEASE (scd) By: Yousef Al Sultan Fatimah Al Khamis.
SICKLE CELL ANEMIA Omar and Yassin.
Mutations Changes to DNA. What are Mutations? Any change to the DNA Mutations in body (somatic) cells can cause cell death or cancer Those in germ (sex)
  Sickle Cell Disease.
Dr. Lamia Wagdy Mohamed Associate Professor of Pharmaceutical Organic Chemistry Faculty of Pharmacy- Cairo University.
So Mutations!  Any change to the quantity or structure of DNA of an organism is known as a mutation.  Mutations can occur in either somatic cells (body.
Samir M. El-Moghazy, Nahed M. Eid, Sahar M. Abou-Seri and Shaimaa M. Abdel-Rahman * Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo.
KAITLIN BANNON SICKLE CELL DISEASE. WHAT IS SICKLE CELL DISEASE? WHERE DID IT COME FROM?
MLAB Hematology Keri Brophy-Martinez Fall 2007 Unit 13: Hemolytic Anemias: Intracorpuscular Defects/ Hemoglobinopathies.
Blood Pathologies. Components of Whole Blood Figure 17.2.
Small Molecule Inhibitors of Phagocytosis for Treatment of Immune Cytopenias D. R. Branch 1, 2, M. K. Purohit 3, I. Scovell 2, A. Neschadim 2, Y. Katsman.
1 Proteins Continued –Tertiary Structure: refers to the overall 3-D shape of a protein produced from bending and folding stabilized by interactions between.
Nehad A. El Sayed, Amal A. H. Eissa, Reem K. Arafa and Ghada F. El Masry* Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University.
SYNTHESIS OF CHOLANE AND LANOSTANE DERIVATIVES
Practical Hematology Lab
of novel 1,2,3-triazolyl appended L-ascorbic acid derivatives
Sickle Cell.
Mendelian Genetics Extended (5.2)
BLOOD donation.
Other Whitesides Research
Results and Discussion
Mutations Mutations are alterations in the DNA of chromosomes.
Do Now: What is a gene? A sequence of nucleotides
Drug Discovery &Development
Anti-cholinesterase inhibitory activities of different varieties
Results and discussion
Sickle Cell Anemia Most common genetic disease in US
Sickle Cell anemia  .
Miss.Shuchismita Behera Miss.Sujata Dixit Dr.G.Bulliyya Dr.S.K.Kar
A REVIEW AND UPDATE ON THE ANTI-ANGIOGENIC AGENT, ABT-510
4.1 Chromosomes, genes, alleles and mutations
Erythrocytapheresis.
CURRENT MANAGEMENT OF SCD IN NIGERIA
Results and Discussion Strategy of Drug Design
Lecturer of Medical Biochemistry
Every living organism inherits a blueprint for life from its parents.
REVISION: GENETICS Topic 4.2 IB Biology Miss Werba.
CHROMOSOMES, ALLELES, GENES & MUTATIONS
Molecular medicine ILA
Hemoglobin metabolism & diseases of hemoglobin
bioactive carboxylates and nitrogen-donor ligands
ALIKO-DANGOTE HALL, EDO UNIVERSITY IYAMHO 22/06/2017
Figure 3 Proportion of patients for whom NEDA
Advanced Higher Chemistry Unit 3(e)
Endari (L-Glutamine)for sickle Cell Disease
The sickle cell allele results from a single point mutation in the gene coding for hemoglobin dominant Negatively charged recessive Hydrophobic.
Advances in the Treatment of Sickle Cell Disease
Dr. Mohammed Hussein M.B.Ch.B, MSC, PhD, DCH (UK), MRCPCH
Pediatric hematologist oncologist
Presentation transcript:

EVALUATION OF SOME SALICYALDEHYDE-DERIVED BAYLIS- HILLMAN ADDUCTS AND           EVALUATION OF SOME SALICYALDEHYDE-DERIVED BAYLIS- HILLMAN ADDUCTS AND COUMARIN DERIVATIVES AS POTENTIAL ANTISICKLING COMPOUNDS by Temitope O. Olomola, Tawakalit O. Shittu, Mojisola O. Olutayo, J.M. Agbedahunsi is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. EVALUATION OF SOME SALICYALDEHYDE-DERIVED BAYLIS- HILLMAN ADDUCTS AND COUMARIN DERIVATIVES AS POTENTIAL ANTISICKLING COMPOUNDS Temitope O. Olomola,a Tawakalit O. Shittu,a, c Mojisola O. Olutayob and J.M. Agbedahunsib aDepartment of Chemistry, Obafemi Awolowo University, Ile-Ife, Osun State, Nigeria. bDrug Research and Production Unit, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Osun State, Nigeria. cDepartment of Chemistry, Edo University, Iyamo, Edo State, Nigeria. Obafemi Awolowo University, Ile-Ife, Nigeria Sickle Cell Disease (SCD) is one of the most common genetic disorders caused by point mutation that changes glutamic acid (Glu6) to Valine (Val6) in the β-chain of haemoglobin. This structural modification leads to abnormal haemoglobin (HbS). Under low oxygen tension, HbSS polymerizes, distorting the biconcave-shaped red blood cells into sickled shape and less flexible thereby causing many clinical features that HbSS carriers suffer. In recent times, haematopoietic stem cell transplant (HSCT) appears to be the only curative treatment for sickle cell disease available today. However, lack of suitably matched donors, cost and the chronic use of immunosuppressive drugs with serious side effects have limited the use of HSCT for the treatment of SCD. Hence, there is need to continue the search for potent drugs that can be used to manage this disorder. Simple Morita-Baylis Hillman adducts have become an important class of bioactive compounds with diverse biological activities such as anticancer, antimalarial, molluscidal activities1, 2. Coumarins form an important pharmacophore in Medicinal Chemistry and they have been reported to exhibit a variety of biological activities usually associated with low toxicity. Coumarins possess pharmacological activities such as anti-HIV anticoagulant, antibacterial, antioxidant, antimalarial, calcium channel blocking activities 3,4. In continuation of our interest in exploring the biological applications of coumarins 5,6,7. we herein report the antisickling potentials of some salicyaldehyde derived Baylis-Hillman adducts and 3-substituted coumarins. In this study, various Baylis Hillman adducts were synthesized and then cyclized to 3-chloromethylcoumarins using acid catalysis (Scheme 1). Also, in an attempt to synthesize a hydroxyurea analogue, 6-chloro-3-(chloromethyl)coumarin (4d) was treated with thiourea in the hope of obtaining a nucleophilic substitution product but rather spectroscopic evidence suggests the formation of chlor ocoumarin-3-sulfinic acid 5d. The synthesized compounds were screened for inhibitory and reversal antisickling activities on HbSS red blood cells using the modified Sofowora method 8. The compounds showed progressive inhibition against sodium metabisulphite induced sickling from 0.5 mg/mL to 4 mg/mL and their activities were comparable with the standard drugs vanillic acid and para-hydroxybenzoic acid (Figures 1 and 2). Figure 1: percentage inhibitory activity of the synthesized compounds and the standard drug Vanillic acid on HbSS red blood cells. Scheme 1. Reagents and conditions: i) DABCO, CHCl3, r.t.; ii) HCl, AcOH, reflux; iii) Thiourea, EtOH/H2O (1:1), r.t. Figure 2: percentage reversal activity of the synthesized compounds and the standard drug p-hydroxybenzoic acid (PHBA) on HbSS red blood cells. Normal shaped red blood cells Figure 3: Micrograph showing the inhibitory activity of compound 4d at 4 mg/mL (× 400 magnification) Figure 4: Micrograph showing the morphology of HbSS blood cells treated with phosphate buffered saline as negative control (× 400 magnification) Figure 7: Rate of HbSS polymerization in the presence of 4 mg/mL of test compounds Sickled RBCs Biconcave shaped RBCs Figure 5: Micrograph showing the reversal activity of compound 5d at 4 mg/mL, (x 400 magnification) Figure 6: Untreated control (Negative control) (x 400 magnification) Figure 8: Rate of HbSS polymerization in the presence of 2 mg/mL of test compounds Acknowledgements The authors acknowledge Tertiary Education Trust Fund (TETFUND) and Obafemi Awolowo University, Ile-Ife, for the grant for Advocacy and Development of Drugs for the Management of Sickle Cell Disorder in South West, Nigeria (2012). References 1. M. Dadwal, R. Mohan, D. Panda, S. Mobin, Chem. Commun. 338-340 (2006) 2. T. Ma, L. Liu, H. Xue, L. Li, J. Med. Chem., 51, 1432-1446 (2008) 3. A.G. Kidane, H.A. Salacinski, K.R. Tiwari, Biomacromolecules, ,5,798 (2004) 4. J. Y. He, W. Zhang, L.C. He, Y. X Cao, Eur. J. Pharm., 573, 170–175. (2007) 5. T.O. Olomola, S. Mosebi, R. Klein, et al., Bioorg. Chem., 57, 1–4 (2014) 6. T.O. Olomola, R. Klein, N. Mautsa, et al., Bioorg. Med. Chem. 21, 1964–1971 (2013) 7. P.T. Kaye, M.A. Musa, X.W. Nocanda, Synthesis, 4, 531‒534 (2003). 8. A. Egunyomi, J.O. Moody, O.M. Eletu, Afr. J. Biotechnol., 8, 20–25 (2009) Creative Commons License

          EVALUATION OF SOME SALICYALDEHYDE-DERIVED BAYLIS- HILLMAN ADDUCTS AND COUMARIN DERIVATIVES AS POTENTIAL ANTISICKLING COMPOUNDS by Temitope O. Olomola, Tawakalit O. Shittu, Mojisola O. Olutayo, J.M. Agbedahunsi is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.